ReviewFrontiers in cardiovascular medicine2026
Proton pump inhibitor co-therapy in patients receiving non-vitamin K antagonist oral anticoagulants: current evidence, gastrointestinal bleeding prevention, and clinical considerations.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-vitamin K antagonist oral anticoagulants (NOACs) are widely prescribed for stroke prevention in atrial fibrillation (AF). Although they reduce intracranial hemorrhage compared with warfarin, gastrointestinal bleeding (GIB), particularly upper GIB (UGIB), remains a clinically significant complication. Proton pump inhibitors (PPIs) are frequently co-prescribed for gastroprotection, yet the available evidence remains largely observational and subject to methodological heterogeneity and confounding by indication. Evidence base and review methodology: We conducted a structured narrative review of nationwide cohort studies, multi-database analyses, randomized trials, and meta-analyses evaluating PPI co-therapy in NOAC-treated populations, with emphasis on clinically adjudicated UGIB outcomes and methodological considerations including confounding by indication and endpoint variability. Clinical evidence and implications for cardiac rhythmology practice: A large Korean nationwide cohort demonstrated that PPI co-therapy in NOAC-treated AF patients was associated with reduced risks of UGIB hospitalization (weighted HR 0.825) and transfusion-requiring UGIB (weighted HR 0.798), particularly in high-risk subgroups. A meta-analysis of approximately 1.97 million oral anticoagulant users reported lower odds of total and major GIB with PPI use (OR ∼0.67-0.68). Randomized evidence suggests biological plausibility for reduction of gastroduodenal bleeding but highlights endpoint specificity. However, heterogeneity across analytic designs underscores persistent residual confounding. Conclusions: PPI co-therapy may represent a clinically pragmatic strategy pending dedicated randomized evidence in high-risk NOAC-treated patients. A pragmatic, risk-stratified approach appears most appropriate while awaiting confirmation from dedicated randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.